This website uses its own and third party technical cookies, solely to ensure enhanced navigation and to gather anonymous statistical navigation data without any user profiling.

If you wish to learn more or deny consent to all or some cookies click here.

If you access any element below this banner you automatically consent to the use of cookies.

Accept

Economic & Financial indicators

Buoyed by the measures taken by the company over the least few years to respond to the scenario changes in pharmaceutical markets, the most significant indicators in our Accounts show a positive trend in the three years 2013-2015. In 2014, total revenues continued their double-digit growth (+14%), thus consolidating 2014’s result (+12%), though not spread uniformly over business areas. In 2015, revenues from the commercial area continued their growth (+14%) as they had already done in 2014 (+16%), thanks to consolidation and to the additional impetus provided by the product portfolio, particularly those products developed internally which carry higher margins. Income from the Manufacturing area has grew up  by 17% in 2015, in an industry in which revenues are dependent on the type of production (either full service or semi-processed) and the commercial dynamics of customers. In addition, in that period, process optimization and continuous investments brought some interesting improvements in industrial profitability.
The company’s economic growth is best represented by the positive trend of the key indicators: in 2015 the EBITDA continued its performance, reaching over 57 million euros, equal to 42% of revenues, which is 24% more than in 2014. The economic results above are reflected in a cash flow position that, partly due to greater efficiencies in capital, has pulled the net financial position into the positive.
Finally, net worth continues to increase, supported by the results achieved and by the reinvestment of part of the profits back into the company.

 

Consolidated Values (in Euro x1000)

Revenues

201520142013

Manufacturing

Variation %

11.477,00

+17,07%

9.803,58

-15,68%

11.627.00

+3,66%

Marketing & Sales

Variation %

123.110,00

+13,89%

108.093,75

+16,68%

92.643,00

+20,11%

Royalties & Downpayments

Variation %

252,00

-60,00%

630,00

-32,62%

935,00

+97,67%

Total

Variation %

134.829,00

+13,76%

118.527,33

+12,66%

105.205,00

+18,44%

 

Results

(Thousand of Euro)

201520142013

Turnover

Variation %

134.839,00

+13,76%

118.527,33

+12,66%

105.205,00

+18,44%

Industrial margin

Variation %

105.766,00

+17,34%

90.137,00

+9,14%

82.590,00

+29,15%

EBITDA

Variation %

57.525,00

+24,33%

46.269,00

+30,52%

35.451,00

+66,24%

EBIT

Variation %

52.387,00

+30,13%

40.256,00

+32,71%

30.334,00

-74,96%

Net profit (loss)

Variation %

34.198,00

+36,67%

25.023,00

+36,66%

18.310,00

+79,74%

Net assets

Variation %

85.823,00

+39,98%

61.613,00

+20,37%

50.938,00

+24,92

Net capital invested

Variation %

57.358,00

0,44%

57.105,00

5,49%

54.133,00

-12,75%

Net financial debits

Variation %

18.135,00

330,86%

4.209,00

231,74%

-3.195,00

84,98%